Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Eligibility

Inclusion Criteria:

1. Blood prostate-specific antigen PSA\>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.

Exclusion Criteria:

1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Conditions2

Locations1 site

Browse More Trials